Zonisamide: Pharmacology and clinical efficacy in epilepsy

CNS Drug Reviews

Volumn 4, Issue 4, 1998, Pages 341-360

  Masuda, Yoshinobu ^a   Ishizaki, Masayuki ^a   Shimizu, Masanao ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Antiepileptic drug; Calcium channel; Neuroprotection; Radical scavenger; Sodium channel; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; ETHOSUXIMIDE; PHENOBARBITAL; PHENYTOIN; TRIMETHADIONE; VALPROIC ACID; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; MOUSE; NEUROPROTECTION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032441352     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00075.x     Document Type: Review

References (110)

1. Acuna-Castroviejo D, Coto-Montes A, Monti MG, Ortiz GG, Reiter RJ. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997;60:23-29.
2. Adams JD, Odunze IN. Oxygen free radicals and Parkinson's disease. Free Radical Biol Med 1991;10:161-169.
3. Adams PR, Galvin M. Voltage-dependent current of vertebrate neurons and their role in membrane excitability. In: Delgado-Escueta AV, Ward AA, Woodbury DM, Porter RJ, eds. Basic mechanisms of the epilepsies. New York: Raven Press, 1986;137-170.
4. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
5. Benveniste H, Drejer J, Schousboe A, Diemer N. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984;43:1369-1374.
6. Bonnekoh P, Barbier A, Oschlies U, Hossman K. Selective vulnerability in the gerbil hippocampus: Morphological changes after 5 min ischemia and long survival times. Acta Neuropathol 1990;80:18-25.
7. Buchanan RA, Bockbrader HN, Chang T, Sedman AJ. Zonisamide pharmacokinetics. Epilepsia 1998;39 (Suppl 2):39.
8. Buchanan RA, French JA, Leppik IE, Padgett CS. Zonisamide drug interactions. Epilepsia 1998;39 (Suppl 2):39.
9. Buchanan RA, Montouris GD, Ayala R, Faught E. Zonisamide efficacy and dose response. Epilepsia 1998;39 (Suppl 2):39.
10. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
11. Castagonoli A, Jr, Chiba K, Trevor AJ. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1985;36:225-230.
12. Chan P, Delanney LE, Irwin L, Langston JW, Di Monte DA. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J Neurochem 1991;57:348-351.
13. Chiba K, Trevor Aj, Castagnoli N, Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984;120:574-578.
14. +, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 1985;128:1229-1232.
15. Davis GC, William AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-254.
16. Fujita Y, Okuno O, Noguchi Y, Nishimura A, Fuchigami T, Harada K. Zonisamide-induced hydropoietic disorder in patients with childhood epilepsy. J Nihon Univ Med Assoc 1995;54:658-662.
17. Fukuda A, Masuda Y. Cerebral protective action of zonisamide and clinical experience in neurosurgical patients. Jpn Pharmacol Ther 1991;19:2011-2018.
18. Ginella M, Gualtieri F, Stein ML. Benzisoxazole and benzisothiazole analogs of auxin. Phytochemistry 1971;10:539-544.
19. Goa KL, Sorkin EM. Gabapentin: A review of its pharmacological properties in epilepsy. Drugs 1993;46:409-427.
20. Hamada K, Ishida S, Yagi K, Seino M. Anticonvulsant effects of zonisamide on amygdaloid kindling in rats. Neuroscience 1990;16:407-412.
21. Hara H, Sukamoto T, Kogure K. Mechanism and pathogenesis of ischemia-induced neuronal damage. Prog Neurol 1993;40:645-670.
22. Hayakawa T, Higuchi Y, Nigami H, Hattori H. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur J Pharmacol 1994;257:131-136.
23. Heikkila RE, Hess A, Duvoisin RC. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Science 1984;224:1451-1453.
24. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 1989;10:171-183.
25. Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988;38:928-931.
26. Heo K. Controlled trials of monotherapy in Korea (Korean zonisamide study group)-Interim report. Satellite symposium II, A novel antiepileptic drug: Zonisamide. 1st AOEO, September 6, 1996, Seoul, Korea.
27. Hori M, Ito T, Oka M, et al. General pharmacology of the novel antiepileptic compound zonisamide. First communication: Effects on central nervous system. Arzneim-Forsch 1987;37:1244-1130.
28. Hougton GW, Richen A, Toseland PA, Davidson S, Falconer MA. Brain concentrations of phenytoin, phenobarbital, and primidone in epileptic patients. Eur J Pharmacol 1975;9:73-78.
29. Ibba M, Vanasia A, Testa R. Differential antagonism of denzimol to various components of metrazole-induced seizures in rats and mice. Pharmacol Res Commun 1985;17:1169-1180.
30. Ito T, Hori M, Masuda Y, Yoshida K, Shimizu M. 3-sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalographic profile. Arzneim-Forsch 1980;30:603-609.
31. Ito T, Hori M, Kadokawa T. Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharge in cats. Epilepsia 1986;27:367-374.
32. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S. Time course and morphology of dopaminergic neuronal death caused by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine. Neurodegeneration 1995;4:257-269.
33. Janner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
34. Kakegawa N. An experimental study on the modes of appearance and disappearance of suppressive effect of antiepileptic drugs on kindled seizures. Psychiatr Neurol Jpn 1986;88:81-98.
35. Kamei C, Oka M, Masuda Y, Yoshida K, Shimizu M. Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats. Arch Int Pharmacodyn 1981;249:164-176.
36. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 1981;239:57-69.
37. Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998;38:166-171.
38. Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neuroscience 1995;21:23-29.
39. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;37:1242-1244.
40. Kopin IJ, Markey SP. MPTP toxicity: Implication for research on Parkinson's disease. Annu Rev Neurosci 1988;11:81-96.
41. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: Long-term observations in seven patients. Epilepsy Res 1998;29:109-114.
42. + administration. Eur J Pharmacol 1990;175:57-61.
43. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analogue synthesis. Science 1983;219:979-980.
44. Langston JW, Forno LS, Robert GS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984;292:390-394.
45. Langston JW, Irwin I. MPTP: Current concepts and controversies. Clin Neuropharmacol 1986;9:485-507.
46. Lee BI. New antiepileptic drugs. II. Clinical use. J Korean Med Sci 1996;11:289-304.
47. Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. Pharmacokinetic and pharmacodynamic tolerance of a new anticonvulsant agent (3-sulfamoylmethyl-1,2-benz-isoxazole) compared to phenobarbital, diphenylhydantoin, and carbamazepine in rats. Arch Int Pharmacodyn 1979;240:79-89.
48. Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamoyl-methyl-1,2-benzisoxazole (AD-810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia 1979;20:623-633.
49. Masuda Y, Karasawa T, Shiraishi Y, Hori M, Yoshida K, Shimizu M. 3-sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneim-Forsch 1980;30:477-483.
50. Masuda Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M. Differential antagonism of anticonvulsants to various components of maximal seizures induced by electroshock or pentylenetetrazol in mice. J Pharm Dyn 1980;3:526-531.
51. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneim-Forsch 1993;43:416-417.
52. Masuda Y, Noguchi H, Karasawa T. Evidence against a significant implication of carbonic anhydrase activity of zonisamide in its anticonvulsive effects. Arzneim-Forsch 1994;44:267-269.
53. Masuda Y, Ochi Y, Kohayakawa H, et al. The novel anticonvulsant zonisamide prevents dopaminergic neurodegeneration induced by MPTP. Jpn J Pharmacol 1998;76 (Suppl 1 ):119.
54. Mather GG, Carlson S, Trager WF, Buchanan RA, Levy RH. Prediction of zonisamide interactions based on metabolic isozymes. Epilepsia 1997;38:108.
55. McJilton J, De Tolendo J, De Cerce J, Huda S, Abubakr A, Ramsay E. Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels. Epilepsia 1996;37 (Suppl 5): 172.
56. Millichap JG. Relation of laboratory evaluation to clinical effectiveness of antiepileptic drugs. Epilepsia 1969;10:315-328.
57. Miller A, Wheatley P, Sawyer DA, Baxter MG, Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: Anticonvulsant profile in mice and rats. Epilepsia 1996;27:483-489.
58. Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H. Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 1990;39:13-17.
59. Minato H, Kikuta C, Fujitani B, Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against focal ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 1997;38:975-980.
60. Miura H. Once-daily dose of zonisamide monotherapy in children with cryptogenic localization-related epilepsies. Satellite symposium II, A novel antiepileptic drug: zonisamide. 1st AOEO, September 6, 1996, Seoul, Korea.
61. Mori A. Reactive oxygen species and mechanism of induction of seizure by guanidine compound. In: Packer L, Hiramatsu M, Yoshikawa T, eds. Free radicals in brain physiology and disorders. San Diego: Academic Press, 1996;3-15.
62. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 1998;30:153-158.
63. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 1985;36:2503-2508.
64. Nielson EB, Suzdak PD, Andersen KE, et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196:257-272.
65. Nunn J, Hodges H. Cognitive deficits induced by global cerebral ischemia: Relationship to brain damage and reversal by transplants. Behav Brain Res 1994;65:1-31.
66. Oguni H, Hayashi K, Fukuyama Y, et al. Phase III study of a new antiepileptic AD-810, zonisamide, in childhood epilepsy. Jpn J Pediatr 1988;41:439-450.
67. Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
68. Owen DL, Ijaz S, Miyashita H, Wishart T, Hewlett W, Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: A histological, in vivo microdialysis and behavioral study. Brain Res 1997;770:115-122.
69. Padgett CS, Bergen DC, French JA, Buchanan RA. Renal calculi associated with zonisamide. Epilepsia 1996;37(Suppl 5):173.
70. Poirier JA, Barbeau A. A catalyst function for MPTP in superoxide formation. Biochem Biophys Res Commun 1985;131:1284-1289.
71. Posner T. Über die Einwirkung von freiem Hydroxylamine auf Cumarine. Chem Ber 1909;42:2523-2532.
72. Posner T, Hess R. Beiträge zur Kenntnis der ungesätigten Verbindungen X. Über die Einwirkung von freier Hydroxylamine auf Cumarine. Chem Ber 1913;46:3816-3833.
73. + administration to mice. Pharmacol Toxicol 1993;72:364-368.
74. Ramsey RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine, by mitochondria. J Biol Chem 1986;261:7585-7587.
75. Rios C, Tapia R. Changes in lipid peroxidation induced by 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion in mouse brain homogenate. Neurosci Lett 1987;77:321-326.
76. Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD-810, CI-912) a novel anticonvulsant. Epilepsy Res 1989;3:138-143.
77. Sanchez-Ramos JR, Michel P, Weiner MJ, Hefti F. Selective destruction of cultured dopaminergic neurons from foetal rat mesencephalon by 1-methyl-4-phenylpyridinium: Cytochemical and morphological evidence. J Neurochem 1988;50:1934-1936.
78. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987;413:185-188.
79. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial. Epilepsy Res 1993;15:67-73.
80. F-D-C REPORTS, Pharmaceutical Approvals Monthly 1998;3:10-12.
81. Seino M, Ito T. Zonisamide. In: Engel J, Jr, Pedlley TA, eds. Epilepsy: A comprehensive textbook. Philadelphia: Lippincott-Raven, 1997;1619-1626.
82. Seino M, Naruto S, Ito T, Miyazaki H, et al. Other antiepileptic drugs. Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995;1011-1023.
83. Seino M, Okuma T, Miyasaka M, et al. Efficacy evaluation of AD-810 (zonisamide). Double-blind study comparing with carbamazepine. Clin Exp Med 1988;144:275-291.
84. Seki T, Kumagai N, Yamada T. Efficacy of zonisamide monotherapy. In: Seki T, Yagi K, eds. Zonisamide in epilepsy therapy. Tokyo: Life Science Publishing, 1996;38-42.
85. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: Preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:450-460.
86. Sherwin AL, Eisen AA, Sokolowski CD. Anticonvulsant drugs in human epileptogenic brain. Arch Neurol 1973;29:73-77.
87. Shinoda M, Akita M, Hasegawa M, Hasegawa T, Nabeshima T. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biol Pharm Bull 1996;19:1090-1092.
88. Smith DL, Keasling HH, Forist AA. The metabolism of N-alkyl-4-bromobenzene sulfoamides in the mouse. J Med Chem 1965;8:520-524.
89. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in rat cultured cerebral neurons. Epilepsy Res 1992;12:21-27.
90. Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997;38:1035-1038.
91. Takano K, Tanaka T, Fujita T, Nakai H, Yonemasu Y. Zonisamide: Electrophysiological and metabolic changes in kainic acid-induced limbic seizure in rats. Epilepsia 1995;36:644-648.
92. Tanaka K, Matsuoka O, Hattori H, Hayashi K, Seto T, Murata R. The dyshydrosis of zonisamide. Osaka J Epilepsy Res 1997;8:31-34.
93. Tanaka S, Kondo S, Tanaka T, Yonemasu Y. Long-term observation of rats after unilateral intra-amygdaloid injection of kainic acid. Brain Res 1988;463:163-167.
94. Tanaka S, Sako K, Tanaka T, Nishihara I, Yonemasu Y. Uncoupling of local blood flow and metabolism in the hippocampal CA3 in kainic acid-induced limbic seizure status. Neuroscience 1990;36:339-348.
95. Tanaka T, Tanaka S, Fujita T, et al. Experimental complex seizures induced by a microinjection of kainic acid into limbic structures. Prog Neurobiol 1992;38:317-334.
96. Taylor CP, MacLean JR, Bockbrader N, et al. Zonisamide (AD-810, CI-912). In: Meldrum BS, Porter RJ, eds. New anticonvulsant drugs. London: John Libbery & Company Ltd., 1986;277-294.
97. Toman JEP, Swinyard EA, Goodman LS. Properties of maximal seizures, and their alteration by anticonvulsant drugs and other agents. J Neurophysiol 1946;9:231-239.
98. Uno H, Kurokawa M, Natsuka K, Yamato Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. Chem Pharm Bull 1976;24:632-643.
99. Uno H, Kurokawa M. Studies on 3-substituted 1,2-benzisoxazole derivatives. III. Mannich reaction of 1,2-benzisoxazole-3-acetic acid. Chem Pharm Bull 1977;25:312-313.
100. Uno H, Kurokawa M. Studies on 3-substituted 1,2-benzisoxazole derivatives. V. Electrophilic substitutions of 1,2-benzisoxazole-3-acetic acid. Chem Pharm Bull 1978;26:3496-3503.
101. Uno H, Kurokawa M, Masuda Y, Nishimura H. Studies on 3-substituted 1,2-benzisoxazole derivatives. VI. Synthesis of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J Med Chem 1979;22:180-183.
102. Vajda F, Williams FM, Davidson S, Falconer MA, Breckenridge A. Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther 1974;15:597-602.
103. Wada Y, Hasegawa H, Yamaguchi N. Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev 1990;12:206-210.
104. Wada Y, Hasegawa H, Yamaguchi N. Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912), in an experimental model of photosensitive epilepsy. Epilepsy Res 1990;7:117-120.
105. Wilder BJ, French JA, Ramsey RE, Bergen C, Padgett CS. Zonisamide interaction and tolerance. Epilepsia 1997;38(Suppl 8):108.
106. Wilder BJ, Penry JK, Dean JC, French JA. Zonisamide efficacy in long-term studies. Epilepsia 1998;39 (Suppl 2):38.
107. Willmore LJ, Sypert GW, Munson JB. Chronic focal epileptiform discharges induced by the injection into rat and cat cortex. Science 1978;200:1501-1503.
108. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies - our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiat 1992;16:79-85.
109. Yagi K, Seino M, Mihara T, et al. Open clinical trial of new antiepileptic drug, zonisamide (ZNA) on 49 patients with refractory epileptic seizures. Seishin Igaku 1987;29:111-119.
110. Zini I, Tomosi A, Glimaldi R, et al. Detection of free radicals during brain ischemia and reperfusion by spin trapping and microdialysis. Neurosci Lett 1992;138:279-282.